We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

21 hedge funds and large institutions have $6.55M invested in Oruka Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more capital invested

Capital invested by funds: $5.75M → $6.55M (+$802K)

0.25% more ownership

Funds ownership: 1.64% → 1.88% (+0.25%)

9% less funds holding

Funds holding: 23 → 21 (-2)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
21
Holders Change
-2
Holders Change %
-8.7%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
6
Closed
4
Calls
$79K
Puts
–
Net Calls
+$79K
Net Calls Change
-$35K

Top Buyers

Rank Fund Capital Flow
1
WSL
Western Standard LLC
California
+$1.11M
2
Renaissance Technologies
Renaissance Technologies
New York
+$12.9K
3
TRCT
Tower Research Capital (TRC)
New York
+$2.55K
4
UBS Group
UBS Group
Switzerland
+$245
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$98

Top Sellers

Rank Fund Capital Flow
1
M
Murchinson
Ontario, Canada
-$103K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$27.1K
3
NM
Newtyn Management
New York
-$26.9K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$22.6K
5
Citadel Advisors
Citadel Advisors
Florida
-$3.13K

ORKA Hedge Fund Activity: Q3 2023 in Review

21 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2023, worth a combined $6.55M — up 14% from $5.75M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ORKA and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.

The largest buyer was Western Standard LLC, adding an estimated $1.11M. The largest seller was Murchinson, exiting entirely with an estimated $103K sold.

  • 21 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2023, down from 23 in Q2 2023.
  • Funds reported $6.55M of Oruka Therapeutics stock for Q3 2023, up 14% quarter-over-quarter.
  • 3 funds opened new Oruka Therapeutics positions in Q3 2023 and 4 closed out, a net change of -1 holder.
  • The largest Oruka Therapeutics buyer in Q3 2023 was Western Standard LLC, an estimated $1.11M added.
  • The largest Oruka Therapeutics seller in Q3 2023 was Murchinson, an estimated $103K sold.

Based on aggregated 13F filings for Q3 2023.